8-K: Gyre Therapeutics Acquires Cullgen, Expands Pipeline

Gyre Therapeutics will acquire Cullgen Inc. in an all-stock transaction valued at approximately $300 million, creating a fully integrated biopharmaceutical company.

Summary

• Gyre Therapeutics, Inc. (Nasdaq: GYRE) is acquiring Cullgen Inc., a privately-held, clinical-stage biopharmaceutical company, in an all-stock transaction valued at approximately $300 million.
• The merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
• The combined entity will be a fully integrated biopharmaceutical company with U.S. and China-based capabilities spanning discovery to commercialization, focusing on inflammatory diseases, cancers, and pain.
• Cullgen brings a targeted protein degrader (TPD) and degrader antibody conjugate (DAC) platform technology and pipeline.
• Gyre's existing commercial assets include ETUARY (pirfenidone capsule) with $105.8 million in net sales in China in 2024 for lung fibrosis.
• Gyre's Hydronidone (F351), an anti-liver fibrosis candidate, is nearing New Drug Application (NDA) submission in China, following positive Phase 3 clinical trial results.
• Cullgen's lead product candidate, CG001419, a pan-TRK degrader, completed a Phase 1 trial for acute post-operative pain with positive top-line results and is expected to initiate a Phase 2 trial in Q2 2026.
• CG001419 is also being studied in a Phase 1 trial for solid tumors.
• Cullgen's second product candidate, CG009301, a GSPT1 degrader, is in a Phase 1 trial for blood cancers.
• Certain officers, directors, and stockholders of both companies have entered into lock-up agreements, restricting share transfers for periods of 180 days, 12 months, and 18 months for one-third of their shares each.
• Support agreements have been signed by key stockholders to vote in favor of the merger and related proposals.
• A Registration Rights Agreement will be entered into, requiring Gyre to file a resale registration statement for certain shares within 45 days post-merger.
• The transaction is expected to close early in the second quarter of 2026, subject to customary closing conditions and regulatory approvals.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive strategic move, combining a commercial-stage company with a cutting-edge technology platform and a robust pipeline, supported by strong clinical data and an experienced leadership team, positioning it for significant future growth.

Positives

• The acquisition creates a fully integrated biopharmaceutical company with expanded capabilities in drug discovery, manufacturing, and commercialization across the U.S. and China.
• Cullgen's targeted protein degrader (TPD) and degrader antibody conjugate (DAC) platform technology significantly enhances the combined entity's drug discovery engine, expanding the 'druggable disease space' up to 100% target accessibility.
• Gyre's Hydronidone (F351) achieved its primary endpoint in a pivotal Phase 3 clinical trial for CHB-associated liver fibrosis in China, demonstrating 52.85% 1-stage fibrosis regression at Week 52 compared to 29.84% for placebo (P = 0.0002).
• Hydronidone also showed a 1-grade inflammation improvement without fibrosis progression in Phase 3 (49.57% vs. 34.82% placebo, P = 0.0246) and has a favorable safety profile with lower serious adverse events than placebo.
• Cullgen's lead candidate, CG001419, a potential first-in-class non-opioid medicine for pain, completed a Phase 1 trial with positive top-line results and is slated for a Phase 2 trial in Q2 2026.
• Gyre's existing commercial product, ETUARY, generated $105.8 million in net sales in China in 2024, providing a strong revenue base.
• The combined company will leverage cost-efficient drug discovery capabilities in China to advance risk-mitigated products globally.
• The transaction is structured as a tax-free reorganization for U.S. federal income tax purposes.

Risks

• The closing of the acquisition is subject to various conditions, which may not be satisfied, potentially preventing the transaction from completing.
• There are uncertainties regarding the timing of the consummation of the acquisition.
• Failure or delay in obtaining necessary regulatory approvals from governmental or quasi-governmental entities could impede the acquisition.
• The acquisition may result in unexpected costs, charges, or expenses.
• The announcement or completion of the acquisition could lead to adverse reactions or changes in business relationships.
• There are inherent uncertainties associated with the development and regulatory approval of product candidates, including potential delays in the commencement, enrollment, and completion of clinical trials.
• The combined entity may face challenges in securing sufficient additional capital to advance its product candidates and preclinical programs.
• There are uncertainties in achieving successful clinical results for product candidates, which could lead to unexpected costs.
• The combined entity may fail to realize the anticipated value from its product candidates and preclinical programs due to inherent risks and difficulties in bringing products to market.

Future Outlook

The combined company aims to be a fully integrated biopharmaceutical entity, leveraging Cullgen's innovative TPD/DAC platform and Gyre's commercial and manufacturing capabilities. Gyre Pharmaceuticals plans to submit an NDA for Hydronidone for conditional approval in China in the first half of 2026, followed by a Phase 3c confirmatory trial. Cullgen expects to initiate a Phase 2 trial for CG001419 in acute pain in the U.S. in Q2 2026, and will continue to advance its preclinical programs, including next-generation degrader-antibody conjugates. Multiple IND submissions and clinical trial completions are anticipated through Q4 2027.

Management Comments

• Dr. Ying Luo, expected President and Chief Executive Officer of Gyre, commented: "We are thrilled about the synergistic coalescing of our companies. Cullgen brings strong drug discovery capabilities and a solid preclinical and clinical pipeline to complement Gyre's existing and highly efficient China-based manufacturing capabilities and sales team. Gyre is already a commercial-stage company with ETUARY on the market in China for the treatment of lung fibrosis and a second product for liver fibrosis, Hydronidone (F351), nearing New Drug Application (NDA), submission in China. Gyre is also exploring the expansion of F351's development in ex-China territories. Following the acquisition, we will have a fully-integrated biopharmaceutical company that will be capable of leveraging emerging drug discovery capabilities in China and strong clinical development in the United States to address unmet medical needs worldwide. I am excited for the potential of TPDs and DACs to drive this Company's future growth globally."
• Mr. Zhang, Chairman of Gyre, commented: "Recently, Gyre, through its majority owned subsidiary, Gyre Pharmaceuticals, had a pre-NDA meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) which supported a conditional approval and priority review eligibility filing for Gyre Pharmaceuticals first-in-class anti-liver fibrosis candidate, Hydronidone, subject to formal approval. As a result, Gyre Pharmaceuticals plans to submit an NDA for Hydronidone for conditional approval in the first half of 2026 and conduct a Phase 3c confirmatory trial to support full approval in China. The addition of Cullgen's TPD/DAC platform and pipeline is expected to enhance our long-term growth prospects. We are excited to have Cullgen colleagues join our team in both the United States and China."

Industry Context

StockSavvy.ai notes that this merger strategically positions the combined entity as a U.S.and China-based biopharmaceutical company, leveraging distinct regional strengths. Cullgen's expertise in targeted protein degradation (TPD) and degrader-antibody conjugates (DACs) places the company at the forefront of a rapidly evolving therapeutic modality, which promises to expand the 'druggable disease space' significantly beyond traditional small molecules. This move is particularly timely given the increasing industry focus on TPDs for previously 'undruggable' targets. Furthermore, the development of CG001419 as a potential first-in-class non-opioid pain medicine addresses a critical unmet medical need exacerbated by the global opioid crisis. Gyre's existing commercial presence and revenue stream in China, particularly with ETUARY and the nearing NDA submission for Hydronidone, provide a stable financial foundation and access to the world's largest healthcare market, which can de-risk and accelerate the development of Cullgen's innovative pipeline assets.

Comparison to Industry Standards

• The TPD and DAC platform technology is presented as a significant advancement, potentially expanding the 'druggable disease space' up to 100% target accessibility, a substantial increase compared to the approximately 37% accessibility for traditional small molecule inhibitors.
• Cullgen's CG001419 is highlighted as a 'potential first-in-class non-opioid medicine for the treatment of pain,' differentiating it from existing opioids and NSAIDs, and other investigational non-opioids like Cebranopadol, Journavx (Suzetrigine, VX-548), VX-993, LTG-001, and STC-004. The filing specifically notes that Journavx did not meet its acute pain primary endpoint, suggesting a potential competitive advantage for CG001419.
• Hydronidone's Phase 3 results for CHB-associated liver fibrosis, showing 52.85% 1-stage fibrosis regression at Week 52 versus 29.84% for placebo (P = 0.0002), represent a statistically significant and clinically meaningful outcome for a first-in-class anti-liver fibrosis candidate, positioning it strongly for market entry in China.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Gyre Therapeutics will experience dilution from the all-stock transaction but gain access to a significantly expanded pipeline and a new, innovative technology platform (TPD/DACs).
• Shareholders of Cullgen Inc. will become shareholders of Gyre Therapeutics, receiving Gyre common or preferred stock, and will be subject to lock-up agreements.
• Employees of Cullgen will join the combined entity, contributing their expertise in targeted protein degradation and drug discovery.
• Key management personnel from both companies will form a new leadership team, with Dr. Ying Luo from Cullgen becoming the President and CEO of Gyre, and Ping Zhang remaining as Executive Chairman.
• Customers and patients stand to benefit from a broader portfolio of therapeutic candidates addressing unmet medical needs in fibrosis, pain, and cancer, including potential first-in-class non-opioid pain treatments.
• Regulatory authorities will be involved in the approval process, particularly regarding the HSR Act and the NMPA's review of Hydronidone's NDA.

Next Steps

• Gyre Pharmaceuticals plans to submit an NDA for Hydronidone for conditional approval in China in the first half of 2026.
• Conduct a Phase 3c confirmatory trial for Hydronidone to support full approval in China.
• Explore the expansion of F351's development in ex-China territories.
• Initiate a Phase 2 trial for CG001419 in acute pain in bunionectomy patients in the U.S. in Q2 2026.
• Continue the Phase 1 trial for CG001419 in solid tumors.
• Continue the Phase 1 trial for CG009301 in blood cancers.
• Progress preclinical programs, including next-generation degrader-antibody conjugates.
• File a resale registration statement with the SEC within 45 calendar days following the Merger Closing Date.
• Convene a meeting of Gyre stockholders to approve the conversion of Company Preferred Stock into Company Common Stock (Conversion Proposal).
• IND submission of Phase 1 trial of CG620953 for inflammatory diseases in China (Q1 2027).
• Completion of the Phase 1 trial of CG009301 for AML in China (2H 2027).
• IND submission of Phase 1 trial of CG923308 for cancer in the U.S. and China (Q1 2027).
• IND submission of Phase 1 trial of F528 COPD in the U.S. and China (Q1 2027).
• Completion of the Phase 1 trial of F230 for PAH in China (Q4 2026).
• Completion of the Phase 1 trial of CG001419 for cancer in China (Q4 2027).

Key Dates

Recommendation

The acquisition of Cullgen by Gyre Therapeutics is a highly strategic move that significantly enhances Gyre's long-term growth prospects. The combined entity gains a cutting-edge targeted protein degradation (TPD) and degrader antibody conjugate (DAC) platform, which is a high-potential area in drug discovery, alongside a robust pipeline of innovative candidates for pain, cancer, and inflammatory diseases. Positive Phase 3 data for Hydronidone (F351) nearing NDA submission in China, coupled with Cullgen's lead pain candidate (CG001419) entering Phase 2, provides strong clinical validation. The merger creates a fully integrated biopharmaceutical company with U.S. and China capabilities, leveraging cost efficiencies and market access. This strategic expansion, strong pipeline, and experienced leadership team position the company for substantial future value creation, making it a compelling 'strong buy' for investors.

Keywords

Merger, Acquisition, Biopharmaceutical, Targeted Protein Degradation, Degrader Antibody Conjugates, Fibrosis, Liver Fibrosis, Pain Management, Oncology, Clinical Trials, Drug Discovery, SEC Filing, GYRE, Cullgen